Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis.
T reatment for chronic lymphocytic (Hashimoto's) thyroiditis consists of L-thyroxine replacement when hypothyroidism develops (1) . Tobacco smoking has numerous effects on thyroid volume, function, and disease, and a protective effect on development of Hashimoto's thyroiditis and thyroid antibodies (2) . Nicotine has antiinflammatory effects (3) but cannot be recommended because it is addictive (4) and toxic (5, 6) . Anatabine, another Solanaceae alkaloid with a similar chemical structure, may have immunomodulatory properties. In a mouse model of thyroiditis, anatabine reduces the incidence and severity of thyroiditis and lowers levels of thyroglobulin antibodies (TgAb) (7) . We designed a clinical trial to assess effects of anatabine dietary supplementation in patients with Hashimoto's thyroiditis.
Materials and Methods

Study sites, patients, and objectives
This was a multicenter, double-blind, placebo-controlled, randomized clinical trial (RCT) enrolling patients with Hashimoto's thyroiditis. IRB approval was obtained and all study patients provided signed informed consent. Patients were recruited from 9 endocrinology clinics in the United States between March 2012 and August 2012.
The primary objective was to collect information on the effects of anatabine supplementation in Hashimoto's thyroiditis patients. Patients taking L-thyroxine were included, but only if their dose was Յ 1.0 mcg/kg/d to exclude individuals with thyroid destruction incapable of responding to any intervention. The main inclusion and exclusion criteria are provided in Supplemental Table 1 .
Study design and randomization
Patients underwent five study site visits over four months. At visit 1 (screening), demographics, vital signs, medical and medication history, and blood and urine samples were collected, and ultrasonography was scheduled. At visit 2 (randomization), patients were randomly assigned to either the anatabine or placebo group. Thereafter, patients returned monthly for visits 3, 4, and 5 to complete study procedures.
Anatabine and placebo lozenge
Anatabine was provided by Rock Creek Pharmaceuticals (Gloucester, MA), and formulated into a flavored mannitol granulation lozenge that also contained fractional replacement doses of vitamins A (834 IU) and D3 (66 IU), in both active and placebo units to reduce the chance that vitamin deficiencies might obscure an anatabine effect on autoimmunity. Anatabine lozenges were administered orally 3 times daily to a target total dose of 0.17-0.25 mg/kg/d. To reduce nicotinic type effects (eg, dizziness, nausea), patients started with 9 mg/d and advanced to the target dose during week two. Patients who took less than 70% of assigned treatment (pill count) were excluded from efficacy analysis.
Study outcomes and assays
The main experimental outcomes were serum TgAb and thyroperoxidase antibodies (TPOAb). Other measures included serum thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), and inflammatory biomarkers (high-sensitivity C-reactive protein (CRP) [hsCRP], interleukin-1 beta [IL-1 beta], IL-6, and IL-18); and ultrasonographic thyroid volume, echogenicity, and vascularity. North Coast Clinical Laboratory (Sandusky, OH) performed the measurements of thyroid function and hsCRP. Assays for TgAb and TPOAb and the three interleukins were performed at Johns Hopkins Immunological Disorder Laboratory (Baltimore, MD). Thyroid ultrasonography was performed at the 9 sites and then sent to a central radiologist who read them blinded (Supplemental Table 2 ).
Statistical analysis
The dataset included thyroid-related variables (TgAb, TPOAb, TSH, FT4, FT3, volume, vascularity, and echogenicity), demographic variables (sex, age, race, and ethnicity), body mass index (BMI), inflammatory markers (hsCRP, IL-1 beta, IL-6, and IL-18), and safety outcomes. Urinary iodine was not measured.
We compared nonadjusted continuous variables between the two treatment groups using a paired t test when normally distributed, Wilcoxon rank-sum test when not normally distributed, and 2 test for categorical variables. All statistical analyses were performed using Stata 12 (Stata Corp., College Station, TX) or JMP 7 (SAS Institute, Cary, NC).
Results
Demographics and baseline characteristics
Among 230 patients screened, 165 were randomized in the study and 146 completed efficacy evaluation (70 receiving anatabine, and 76 placebo; Supplemental Figure  1 ). Patients were predominantly female, Caucasian, and non-Hispanic (Supplemental Table 2 ). Seventy-seven patients reported taking levothyroxine (36 on anatabine and 41 on placebo). There were no significant differences between groups with respect to demographic and baseline characteristics.
Thyroid autoantibodies
The absolute change in mean TgAb levels between baseline and weeks 4, 8, and 12 revealed a significantly greater TgAb reduction in patients taking anatabine relative to those taking placebo by week 12 (P ϭ .027, Figure  1C) . TgAb values decreased by 46.2 (Ϯ101.1) WHO units for the anatabine group and only 3.9 (Ϯ83.9) WHO units for placebo by week 12. The proportion of patients with a Ͼ 20% decrease in TgAb was greater in the anatabine group (47%) than the placebo group (28%) at week 12 ( Figure 1D , P ϭ .023). Due to significant heteroscedasticity in TgAb values, data were categorized based on reduction from baseline: Ն25, Ն50, Ն75, and Ն 100 WHO unit reductions). By week 12, the percentage of patients on anatabine with reductions in TgAb Ն 25, Ն50, Ն75, and Ն 100 WHO units was significantly greater than in the placebo group for each category (all P Ͻ .05; Supplemental Figure 2) . No significant differences were found for TPOAb.
Subgroup analysis of patients taking levothyroxine (n ϭ 36) compared to those not (n ϭ 34) revealed a substantial decrease in TgAb from baseline at week 12 in the anatabine group on levothyroxine therapy (P ϭ .008). Additional analysis conducted with 31 patients in the anatabine group taking levothyroxine doses of Յ 
Serological thyroid function tests, inflammatory biomarkers, and thyroid ultrasonography
There were no significant changes or treatment group differences in serum thyroid function tests and inflammatory biomarkers, or ultrasonography measures (Supplemental Table 3 ).
Adverse events and safety
More patients in the anatabine group (81%) reported AEs relative to the placebo group (44%, P Ͻ .05) ( Table  1 ). The most common AEs on anatabine were dizziness (36%), nausea (8%), and headaches (7%) during dose titration, and paresthesia (7%).
Seven (8%) patients on anatabine and one (1%) on placebo withdrew from the study due to AEs; these were all considered mild or moderate. One patient on anatabine reported a serious AE, chest pain, which was evaluated and found to be of noncardiac origin, considered unrelated to study treatment, resolved without complications, and did not recur with resumption of anatabine.
There were no significant abnormalities in clinical laboratory values attributed to anatabine, and no clinically significant effects of either treatment on vital sign measures.
Discussion
This study's results show a selective decrease in TgAb but not TPOAb in patients with Hashimoto's thyroiditis after 12 weeks of anatabine supplementation. Anatabine is an alkaloid found in plants of the Solanaceae family, including tobacco, tomatoes, potatoes, peppers, and eggplants (8) . Although dietary anatabine's mechanism of action on thyroid autoimmunity remains to be elucidated, it may produce immunomodulatory effects through activation of alpha4beta2 or alpha7 cholinergic receptors like nicotine and other structurally related agonists (9, 10, 11) . In a mouse model of thyroiditis, anatabine decreases thyroidal IL-1 beta and IL-18 levels (7), and in other experimental disease models it suppresses the inflammatory transcription factors STAT3 and NF-kB (12, 13, 14) .
Multiple epidemiological studies have reported a protective effect of smoking on autoimmune hypothyroidism and thyroid antibodies (Supplemental Table 4 ). Noteworthy are studies showing selective effects of smoking on TgAb. Analysis of 4,125 randomly selected Danes found a negative association between smoking and presence of thyroid antibodies; the most pronounced association was found between smoking and TgAb, irrespective of TPOAb status (15) . Analysis of a prospective population-based cohort of 9,362 pregnant mothers in Finland showed that mothers who smoked before pregnancy had lower TgAb prevalence than nonsmokers (2.5% vs 4.7%, P Ͻ .001), whereas prevalences of TPOAb were similar (16) .
Although TPOAb and TgAb are typically both measured for diagnostic purposes and often fluctuate in parallel with the disease course, the quantitative correlation between them is rather poor. Carlé et al (17) analyzed 145 patients with newly diagnosed autoimmune hypothyroidism and noted a correlation between TPOAb and TgAb (P Ͻ .001), but a low Pearson's r-squared value (0.11). Analysis of NHANES data from 2007-2008 showed a similarly low r-squared value of 0.21 in more than 6,200 Americans (unpublished data). For each parameter, patients who had at least one event were included in the analysis; i.e. patients could have experienced multiple events within a particular parameter, but were only counted once. b Determined by the Investigator as either possibly or probably related to study treatment. c One patient in the anatabine group reported a serious adverse event (chest pain) that was considered unrelated to study treatment, did not result in withdrawal from the study, and did not recur following resumption of active study product. d Anatabine dose reductions occurred with similar frequency regardless of dose group assignment, and occurred most often for patients prior to their week 4 site visit (i.e. the first in-person visit following initiation of dosing). e Five of the patients in the anatabine group who had dose reductions subsequently withdrew from the study. The efficacy analysis group for anatabine (n ϭ 70) consisted of 24 (34%) patients who had a dose reduction, and 46 (66%) patients who completed the study at their maximum assigned dose.
